ZA989461B - Methods and compositions for the treatment of autoimmune disease using heat shock proteins - Google Patents

Methods and compositions for the treatment of autoimmune disease using heat shock proteins

Info

Publication number
ZA989461B
ZA989461B ZA989461A ZA989461A ZA989461B ZA 989461 B ZA989461 B ZA 989461B ZA 989461 A ZA989461 A ZA 989461A ZA 989461 A ZA989461 A ZA 989461A ZA 989461 B ZA989461 B ZA 989461B
Authority
ZA
South Africa
Prior art keywords
compositions
treatment
methods
autoimmune disease
heat shock
Prior art date
Application number
ZA989461A
Other languages
English (en)
Inventor
Pramod K Srivastava
Rajiv Y Chandawarkar
Original Assignee
Univ Fordham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Fordham filed Critical Univ Fordham
Publication of ZA989461B publication Critical patent/ZA989461B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA989461A 1997-10-16 1998-10-16 Methods and compositions for the treatment of autoimmune disease using heat shock proteins ZA989461B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/951,789 US6007821A (en) 1997-10-16 1997-10-16 Method and compositions for the treatment of autoimmune disease using heat shock proteins

Publications (1)

Publication Number Publication Date
ZA989461B true ZA989461B (en) 1999-04-21

Family

ID=25492154

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA989461A ZA989461B (en) 1997-10-16 1998-10-16 Methods and compositions for the treatment of autoimmune disease using heat shock proteins

Country Status (7)

Country Link
US (1) US6007821A (de)
EP (1) EP1024701A4 (de)
JP (1) JP2002514570A (de)
AU (1) AU756472B2 (de)
CA (1) CA2306062A1 (de)
WO (1) WO1999018801A1 (de)
ZA (1) ZA989461B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6455493B1 (en) 1996-09-20 2002-09-24 University Of New Mexico Methods for using heat shock proteins
EP0950061A4 (de) 1996-09-20 2000-04-12 Univ New Mexico Hitzeschockproteinkomplexe
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
IT1290828B1 (it) * 1997-03-25 1998-12-11 Zetesis Spa Uso di proteine estraibili da organi animali per la preparazione di medicamenti per il trattamento di condizioni patologiche
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
NZ538399A (en) * 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US20060121051A1 (en) * 1998-02-19 2006-06-08 Kenten John H Heat shock fusion-based vaccine system
WO1999042121A1 (en) * 1998-02-20 1999-08-26 University Of Miami Modified heat shock protein-antigenic peptide complex
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
EP1076091A1 (de) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Arzneimittel für die Verhinderung und/oder Behandlung von Herzischämie, peripheren Gefässkrankheiten, Tumoren und Wunden
WO2001012216A1 (en) * 1999-08-13 2001-02-22 Proteinix Company Heat shock fusion-based vaccine system
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20030108957A1 (en) * 2002-07-19 2003-06-12 The Wistar Institute Of Anatomy And Biology Biocidal molecules, macromolecular targets and methods of production and use
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
US7179462B2 (en) * 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
EP1286693A4 (de) * 2000-06-02 2005-07-13 Univ Connecticut Health Ct Komplexe aus alpha-2-makroglobulin und antigenen molekülen zur immuntherapie
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
NZ523408A (en) 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
US20040175360A1 (en) * 2000-06-29 2004-09-09 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
JP4676048B2 (ja) * 2000-07-10 2011-04-27 生化学工業株式会社 脱髄性疾患処置剤
JP5087201B2 (ja) * 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
AU2002220038A1 (en) 2000-11-01 2002-05-15 Alberto Martini Immunomodulatory peptides derived from heat shock proteins and uses thereof
KR20030074787A (ko) 2001-02-05 2003-09-19 스트레스젠 바이오테크놀러지스 코포레이션 Ｂ형 간염 바이러스 치료
CA2444391A1 (en) * 2001-04-13 2002-10-24 Becton Dickinson And Company Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption
WO2002094259A1 (en) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US20070129307A1 (en) * 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
WO2003001204A2 (en) * 2001-06-22 2003-01-03 The University Of British Columbia Type 1 diabetes diagnostics and therapeutics
CN1253220C (zh) 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
EP1551957A4 (de) * 2001-10-01 2007-01-24 Univ Duke Isoliertes polypeptid der grp94-ligandenbindungsdomäne und dafür codierende nukleinsäure, kristalline form davon sowie durchmusterungsverfahren, bei dem es verwendet wird
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US20030216315A1 (en) * 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
WO2003096967A2 (en) 2002-05-21 2003-11-27 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
BR0313890A (pt) * 2002-08-30 2005-07-26 Becton Dickinson Co Método de controle da farmacocinética de compostos imunomoduladores
EP1576124A2 (de) * 2002-10-07 2005-09-21 Antigenics Inc. Hitzeschockprotein bindende fragmente von cd91 sowie verwendungen davon
EP1578459A3 (de) * 2002-10-25 2005-11-23 University of Connecticut Health Center Gerät und verfahren für die immuntherapie von krebs durch kontrollierte zelllyse
US9701725B2 (en) * 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP1625148B1 (de) * 2003-05-21 2012-09-26 Biotech Tools S.A. Peptidkomplex
JP2007500251A (ja) * 2003-06-13 2007-01-11 ベクトン・ディキンソン・アンド・カンパニー 生物学的に活性な作用物質の改良型皮内送達
US20050180952A1 (en) * 2003-08-26 2005-08-18 Pettis Ronald J. Methods for intradermal delivery of therapeutics agents
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
WO2005091922A2 (en) * 2004-03-03 2005-10-06 Becton, Dickinson And Company Methods and devices for improving delivery of a substance to skin
EP1744784A2 (de) * 2004-05-11 2007-01-24 Becton, Dickinson and Company Schmerzmittelformulierungen und verfahren zu deren anwendung
US20060002932A1 (en) * 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CA2594040A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CA2595726A1 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
WO2007038083A2 (en) * 2005-09-21 2007-04-05 New York University Heat shock proteins from mycobacterium leprae and uses thereof
US7377231B2 (en) * 2005-10-19 2008-05-27 Ming-Liang Tsai Retractable pet house
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US8742068B2 (en) * 2007-07-06 2014-06-03 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
JP2011515399A (ja) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ 熱ショックタンパクｇｐ９６ワクチン接種及びそれを用いた方法
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
US8540985B2 (en) 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
AU2009316371B2 (en) * 2008-11-21 2014-02-20 University Of Miami HIV/SIV vaccines for the generation of mucosal and systemic immunity
WO2010086418A1 (en) * 2009-01-29 2010-08-05 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
EP2673050B1 (de) * 2011-02-10 2016-03-30 Alfa Biogene International B.V. Hsp pflanzlichen ursprungs zur behandlung von nahrungsmittelallergie
US20140341935A1 (en) * 2011-08-30 2014-11-20 Loyola University Chicago MUTANT HSP70i TO PREVENT AUTOIMMUNE DISEASE
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
CN105749251A (zh) * 2016-04-08 2016-07-13 中国科学院微生物研究所 热休克蛋白gp96在预防和治疗1型糖尿病中的应用
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
KR20210059796A (ko) 2016-04-29 2021-05-25 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
CN105963681B (zh) * 2016-05-09 2019-09-06 佛山热休生物技术有限公司 热休克蛋白gp96在治疗系统性红斑狼疮中的应用
CN106039287B (zh) * 2016-06-28 2019-12-31 中国科学院微生物研究所 热休克蛋白gp96在治疗类风湿性关节炎中的应用
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정
WO2023064942A1 (en) 2021-10-14 2023-04-20 Tiziana Life Sciences Plc Methods of suppressing microglial activation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268170A (en) * 1986-09-09 1993-12-07 Yeda Research And Development Co., Ltd. Methods of treatment and diagnosis of autoimmune diseases, especially arthritic conditions
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
ATE127345T1 (de) * 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
US5578303A (en) * 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
ES2171454T3 (es) * 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
PT731811E (pt) * 1993-11-30 2005-04-29 Univ Queensland Chaperonina 10
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
AU696637B2 (en) * 1994-06-09 1998-09-17 Delta-Crystallon B.V. Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
WO1997024140A1 (en) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
EP0937258A2 (de) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Humane durch zellstress regulierte mhc class i gene
JP4484969B2 (ja) * 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Also Published As

Publication number Publication date
CA2306062A1 (en) 1999-04-22
EP1024701A1 (de) 2000-08-09
WO1999018801A9 (en) 1999-07-01
EP1024701A4 (de) 2000-12-06
AU1086299A (en) 1999-05-03
JP2002514570A (ja) 2002-05-21
AU756472B2 (en) 2003-01-16
US6007821A (en) 1999-12-28
WO1999018801A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
ZA989461B (en) Methods and compositions for the treatment of autoimmune disease using heat shock proteins
ZA967758B (en) Therapeutic and prophylactic methods using heat shock proteins
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
HUP9904239A3 (en) High level expression of proteins
IL132704A0 (en) Methods and compositions for the selective modification of nucleic acids
PL336420A1 (en) Improved methods of processing activated protein c
HUP0004230A3 (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
IL136454A0 (en) Compositions and methods for inducing gene expression
IL135338A0 (en) Methods and compositions for the selective modification of nucleic acids
ZA985704B (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
AU7361900A (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
EP0777474A4 (de) Verfahren zur behandlung von entzündlichen gelenkerkrankungen
HUP0003206A3 (en) Methods of preparing and purifying 9-nitro-20-camptothecin
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
EP0998293A4 (de) Behandlungen von zytokin-bedingten krankheiten
IL129024A0 (en) Use of proteins as agent against autoimmune diseases
IL128570A0 (en) Protein kinases and uses thereof
ZA9710934B (en) Compositions and methods for administering pneumococal dna
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
HUP0000280A3 (en) Canine ob protein compositions and methods
IL141551A0 (en) Compositions and methods for the treatment of immune related diseases